Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-like 3

Angiopoietin-like 3

Brief Information

Name:Angiopoietin like 3
Target Synonym:Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Mouse Angiopoietin-like 3, His TagMouse Angiopoietin-like 3, His Tag (Cat. No. AN3-M52H3) ELISA bioactivity

Immobilized Mouse Angiopoietin-like 3, His Tag (Cat. No. AN3-M52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (QC tested).

Human Angiopoietin-like 3, His TagHuman Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) ELISA bioactivity

Immobilized Human Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.5-2 ng/mL (QC tested).

Synonym Name



Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Evinacumab REGN-1500 Approved Regeneron Pharmaceuticals Inc Evkeeza EU Hypercholesterolemia Regeneron Ireland Designated Activity Company 2021-02-11 Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LY-3561774 LY-3561774; DCR-CM-1; DCR-CM1 Phase 1 Clinical Dyslipidemias; Metabolic Diseases; Cardiovascular Diseases Details
LY-3475766 LY-3475766 Phase 1 Clinical Eli Lilly And Company Dyslipidemias Details
ARO-APOC3 ARO-APOC3 Phase 3 Clinical Arrowhead Pharmaceuticals Hypertriglyceridemia; Hyperlipoproteinemia Type I Details
ARO-ANG3 ARO-ANG3 Phase 2 Clinical Arrowhead Pharmaceuticals Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Dyslipidemias; Hyperlipoproteinemia Type II; Lipid Metabolism Disorders Details
Vupanorsen ISIS-703802; PF-07285557 Phase 2 Clinical Ionis Pharmaceuticals Inc Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Hyperlipoproteinaemia type IIa; Hyperlipoproteinemia Type I; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II Details
LNA-043 LNA-043 Phase 2 Clinical Novartis Pharma Ag Knee Injuries; Osteoarthritis, Knee; Osteoarthritis; Wounds and Injuries Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message